This is a routine director sale tied to RSU vesting, not a C-suite exit. No material bearish signal. Monitor for actual Form 4 filings to confirm execution, but no immediate trading action warranted.
APGE drugs
APGE drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 13 $83.94entry
- T+1 · 6mo ago −0.04%α −0.81% · $83.91
- T+5 · 6mo ago −3.04%α −2.90% · $81.39
- T+20 · 5mo ago +6.62%α +7.24% · $89.50
- T+60 · 3mo ago +60.64%α +56.20% · $134.84
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Director Michael Thomas Henderson filed a Form 144 on May 13, 2026, indicating intent to sell 60,000 shares of Apogee Therapeutics common stock, with an approximate market value of $4.95 million based on the filing date price. This is a routine insider sale by a director, not a C-suite officer, and the shares appear to originate from RSU vesting, reducing its signaling significance.
Key Facts
- Director Michael Thomas Henderson filed Form 144 to sell 60,000 shares.
- Estimated sale value ~$4.95 million based on filing date market price.
- Shares acquired via RSU vesting from October 2023 through January 2024.
- Henderson is a director, not CEO/CFO, reducing insider signal weight.
- Recent insider activity (30d) shows 3 sells totaling $556K, all small relative to market cap.
- Company market cap is $6.2B; the proposed sale represents ~0.08% of shares outstanding.
Financial Impact
Proposed sale of 60,000 shares valued at ~$4.95 million, representing a small fraction of market cap.
Risk Factors
- Insider sale could be misinterpreted as negative signal by the market.
- If additional large insider sales follow, sentiment could shift.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001949846-26-000273 |
| Document: 0001949846-26-000273-index.html | 0001949846-26-000273 |
| Document: 0001949846-26-000273.txt | 0001949846-26-000273 |
Track record
31 reports on APGE
9 of 11 bullish or bearish reports moved the stock their way by T+20. Best: +73.31% at T+60 after the May 27, 2026 report. 12 of 13 went positive at some point.
Filters
- Sep 14, 20269w ago 15-12G Neutral 4/10 No price data
- Sep 3, 202610w ago 25-NSE Bullish 8/10 Entry $135.06 No price data
- Sep 3, 202610w ago 8-K Bullish 8/10 Entry $135.06 No price data
- Aug 11, 202613w ago 8-K Bullish 7/10 Entry $134.55 No price data
- Aug 10, 202614w ago 8-K Bullish 8/10 No price data
- Aug 10, 202614w ago Press Release Bullish 8/10 Entry $134.65 No price data
- Aug 6, 202614w ago Institutional Cluster Mixed 5/10 Entry $134.49 to $135.07 ▲ +0.43% −0.17% vs SPY
- Aug 3, 202615w ago DEFA14A Bullish 5/10 Entry $134.19 to $135.08 ▲ +0.66% +1.90% vs SPY
- Jul 10, 202618w ago Insider Cluster Neutral 2/10 Entry $133.82 to $134.65 ▲ +0.62% −2.56% vs SPY
- Jun 26, 202620w ago DEFA14A Bullish 6/10 Entry $132.61 to $134.28 ▲ +1.26% +1.54% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers